Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Anti-cancer drug developed for non-hodgkin's lymphoma
July 20, 2015
By: Tim Wright
Editor-in-Chief, Contract Pharma
CASI Pharmaceuticals Inc., a biopharmaceutical company focused on cancer therapies for the global market with a commercial focus on China, has introduced Zevalin at hospitals in Hong Kong to patients with indicated non-Hodgkin’s lymphoma (NHL), including at Hong Kong Sanatorium & Hospital. The drug will be supplied by CASI and its local partner, Global Medical Solutions Hong Kong Limited. Zevalin (ibritumomab tiuxetan) is a FDA-approved product indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL). It is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin’s Lymphoma who achieve a partial or complete response to first-line chemotherapy. Zevalin builds on the combined therapeutic effects of a targeted biologic monoclonal antibody augmented with a beta-emitting radioisotope. CASI Pharmaceuticals holds the exclusive marketing rights to Zevalin in greater China, including Taiwan, Hong Kong and Macau, and is launching the drug in Hong Kong as the first of its marketing territories. “We are very pleased that we can now provide Zevalin in Hong Kong hospitals and help address the unmet medical needs there,” Rong Chen, chief medical officer, CASI. “Zevalin is clinically proven to have significantly higher complete response rate (CR) and overall response rate (ORR) in relapsed or refractory, low-grade or follicular B-cell NHL patients in comparison with rituximab. It is also clinically proven to be efficacious with quite high CR and ORR in patients who are not responding or relapsed from rituximab therapy.” “Although Hong Kong is a relatively small market, it is strategically important as it will enable us to gain clinical knowledge and experience for Zevalin in a Chinese patient population, which we believe will have positive impact in market penetration when Zevalin is approved and becomes available in our greater China markets,” said Ken Ren, chief executive officer, CASI. According to the company, it is on track to file its import drug registration application for Zevalin with the Chinese FDA by the third quarter of this year, followed by the filing of its marketing application and initiation of commercial activities for Zevalin in Taiwan. In addition to Zevalin, the CASI has exclusive marketing rights in greater China to Marqibo and Evomela (CE-Melphalan HCl) for injection. Both were acquired from Spectrum Pharmaceuticals.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !